S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

$44.66
+0.55 (+1.25%)
(As of 03/27/2024 ET)
Today's Range
$43.83
$44.85
50-Day Range
$42.03
$52.01
52-Week Range
$33.32
$54.44
Volume
886,196 shs
Average Volume
1.01 million shs
Market Capitalization
$6.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.67

Ionis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
24.6% Upside
$55.67 Price Target
Short Interest
Bearish
7.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.37mentions of Ionis Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$7.29 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.92) to ($3.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.51 out of 5 stars

Medical Sector

290th out of 939 stocks

Pharmaceutical Preparations Industry

130th out of 435 stocks

IONS stock logo

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

IONS Stock Price History

IONS Stock News Headlines

Are These 5 Undervalued Stocks Ready to Break Out?
Albemarle Corp. NYSE: ALB, Ionis Pharmaceuticals Inc. NASDAQ: IONS, Insulet Corp. NASDAQ: PODD, Hess Corp. NYSE: HES and Wynn Resorts Ltd. NASDAQ: WYNN are among undervalued stocks that beat analysts earnings views.
Are These 5 Undervalued Stocks Ready to Break Out? (IONS)
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Ionis to hold olezarsen Phase 3 data webcast
IONS Oct 2024 50.000 put
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
IONS Apr 2024 75.000 call
Q4 2023 Agenus Inc Earnings Call and Corporate Update
Madrigal wins FDA approval of first drug for MASH
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Ionis to present at upcoming investor conferences
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
927
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$55.67
High Stock Price Target
$72.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+24.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Net Income
$-366,290,000.00
Pretax Margin
-42.40%

Debt

Sales & Book Value

Annual Sales
$788 million
Book Value
$2.70 per share

Miscellaneous

Free Float
141,890,000
Market Cap
$6.51 billion
Optionable
Optionable
Beta
0.40
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives


IONS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares.
View IONS analyst ratings
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price target for 2024?

12 brokerages have issued twelve-month price targets for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $28.00 to $72.00. On average, they predict the company's share price to reach $55.67 in the next year. This suggests a possible upside of 24.6% from the stock's current price.
View analysts price targets for IONS
or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2024?

Ionis Pharmaceuticals' stock was trading at $50.59 on January 1st, 2024. Since then, IONS stock has decreased by 11.7% and is now trading at $44.66.
View the best growth stocks for 2024 here
.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 9,670,000 shares, an increase of 6.1% from the February 29th total of 9,110,000 shares. Based on an average daily volume of 1,190,000 shares, the short-interest ratio is presently 8.1 days. Currently, 7.2% of the shares of the stock are short sold.
View Ionis Pharmaceuticals' Short Interest
.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IONS earnings forecast
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.72. The company earned $325 million during the quarter, compared to analysts' expectations of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative trailing twelve-month return on equity of 90.29%. Ionis Pharmaceuticals's revenue for the quarter was up 113.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.37) EPS.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.90%), Vanguard Group Inc. (9.75%), Bellevue Group AG (6.07%), Clearbridge Investments LLC (3.28%), Wellington Management Group LLP (3.17%) and Price T Rowe Associates Inc. MD (2.97%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen.
View institutional ownership trends
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IONS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners